Upstream Bio's Verekitug Shows Clinically Meaningful Improvements in 79% of Patients in New Phase 2 CRSwNP Data
UPB is trading near its 52-week low of $5.85 (8.7% above the low) on elevated volume (2.2× avg).
Summary
Upstream Bio presented new responder analyses from its Phase 2 VIBRANT trial for verekitug in chronic rhinosinusitis with nasal polyps (CRSwNP). The data showed a significant majority of participants achieved clinically meaningful improvements, including 79% for nasal polyp score, 72% for nasal congestion, and 83% for total symptom score. This follows the company's May 18th announcement of positive Phase 2 data and provides deeper detail on the drug's efficacy. These strong responder rates reinforce verekitug's potential and support its differentiation, especially with quarterly dosing. The company plans to initiate Phase 3 trials for verekitug in both CRSwNP and severe asthma in Q1 2027.
At the time of this announcement, UPB was trading at $6.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $332M. The 52-week trading range was $5.85 to $33.68. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.